2017-08-25 13:36:00 Fri ET
stock market competition macrofinance stock return s&p 500 financial crisis financial deregulation bank oligarchy systemic risk asset market stabilization asset price fluctuations regulation capital financial stability dodd-frank
The U.S. Treasury's June 2017 grand proposal for financial deregulation aims to remove several aspects of the Dodd-Frank Act 2010 such as annual macro stress tests, supervisory bank capital reviews, proprietary trading restrictions, and so forth. Fed Vice Chair Stanley Fischer warns that the current financial deregulation can be extremely dangerous and myopic: "It took almost 80 years after 1930 for America to experience another [global] financial crisis that could have been of that magnitude... now after 10 years everyone wants to return to a status quo before the [next financial downturn]."
As prior monetary policy turns out to be a rather ineffective solution for the post-crisis macro malaise, fiscal stimulus garners a lion's share of public attention toward lower income taxation and indefinite tax holiday for corporate offshore cash repatriation. Regardless of whether the Dodd-Frank supervisory stress instruments should remain for a more stable U.S. banking system, the Fischer comment rings the alarm bell of fiscal quid pro quo for weak monetary stimulus. This information exchange offers valuable food for thought to the typical stock market investor. While the trend can be his or her friend, the investor needs to weigh the pros and cons of short-term stock price momentum vis-a-vis the close nexus between long-term economic fluctuations and stock market gyrations.
If any of our AYA Analytica financial health memos (FHM), blog posts, ebooks, newsletters, and notifications etc, or any other form of online content curation, involves potential copyright concerns, please feel free to contact us at service@ayafintech.network so that we can remove relevant content in response to any such request within a reasonable time frame.
2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be
2019-07-09 15:14:00 Tuesday ET

The Chinese new star board launches for tech firms to list at home. The Nasdaq-equivalent new star board serves as a key avenue for Chinese tech companies t
2023-11-07 11:31:00 Tuesday ET

Joel Mokyr suggests that economic growth arises from a change in cultural beliefs toward technological progress. Joel Mokyr (2018) A culture
2020-07-26 15:29:00 Sunday ET

Firms and customers create value and wealth together by joining the continual flow of small batches of lean production to the lean consumption of cost-effec
2018-10-17 12:33:00 Wednesday ET

The Trump administration blames China for egregious currency misalignment, but this criticism cannot confirm *currency manipulation* on the part of the Chin
2019-03-15 13:36:00 Friday ET

CNBC stock host Jim Cramer recommends both Caterpillar and Home Depot as the U.S. bull market is likely to continue in light of the recent Fed Chair comment